Johnson & Johnson, AstraZeneca researching vaccine modification to address rare blood clot risk
Johnson & Johnson (J&J) and AstraZeneca are researching vaccine modification to address the rare blood clot risk associated with the companies’ coronavirus vaccines.
People familiar with the situation told The Wall Street Journal the two companies and people at the University of Oxford are in the early stages of research to identify why the vaccines are causing rare blood clots and what can be done to stop it.
The sources say it is not clear yet if the vaccine can be modified or if it would make commercial sense to do so.
Officials say the benefits outweigh the risk with the AstraZeneca and J&J vaccines since the risk of blood clots is so small.
It is unknown if the risk of blood clots is coming from the process used to make the vaccines or the ingredients inside them.
Figuring out how to solve the risk of blood clots could boost public confidence and allow the companies to make money off the vaccines once the pandemic is over.
Public confidence is key as many countries, including the U.S., are struggling to get their population vaccinated.
“We strongly support awareness of the signs and symptoms of this very rare event to ensure the correct diagnosis, appropriate treatment and expedited reporting by health care professionals. We also support continued research and analysis as we work with medical experts and global health authorities,” J&J said in a statement to The Hill.